Association between genetic variants and the risk of nivolumab-induced immune-related adverse events (irAEs) - Supplementary material

dataset

posted on 2022-10-21, 08:38 authored by Chihiro Udagawa, Mari Hara Nakano, Teruhiko Yoshida, Yuichiro Ohe, Ken Kato, Taisei Mushiroda, Hitoshi Zembutsu

Supplementary Table 1. Patient demographics and clinical characteristics (nivolumab-induced hypothyroidism).

Supplementary Table 2. Profile of nivolumab-induced irAEs.

Supplementary Table 3. Association results of 90 SNPs which showed smaller P values in combined analysis than those in GWAS.

Funding

Japan Agency for Medical Research and Development, (Grant / Award Number: 'JP20km0405201') JSPS KAKENHI, (Grant / Award Number: 'JP20K16400')

History

Usage metrics

Keywords

genome-wide association study (GWAS)immune checkpoint inhibitor immune-related adverse event (irAE)nivolumab pharmacogenomics

Licence

CC BY-NC-ND 4.0